Dr. Singh shares how Indian pharmaceutical companies can navigate stricter global regulations, foster sustainable quality, embrace digital transformation, and strengthen their position in the global pharmaceutical market.
GSK has received Early FDA Approval for its new lung cancer drug, Jideytro. The decision marks a major milestone for the company as it enters the competitive market for targeted lung cancer therapies.
Trump’s new tariff plan has raised fresh concerns for Indian pharma companies that depend on the US market. US President Donald Trump announced a phased tariff policy for imported generic drugs.
International researchers have raised fresh concerns over papaya cancer research conducted by Tata Memorial Centre. They have questioned whether the study provides enough evidence to support its conclusions.
India has cleared Fasenra expansion as AstraZeneca targets severe asthma patients with a wider treatment option.
Merck’s cholesterol pill is poised to reshape the global cardiovascular drug landscape, this comes with the latest approval from the U.S. Food and Drug Administration for its first-in-class oral PCSK9 inhibitor
The fight against tuberculosis is no longer just about better medicines or advanced diagnostics, rather, it is increasingly about speed
India strengthening of healthcare quality and innovation has received a major boost with a new collaboration between the central and state governments
The new regulatory move on brand name extension marks a significant step strengthening drug safety and reducing patient confusion in Indian pharma
India’s healthcare system is set for a major boost through medical insurance expansion. The government is considering doubling coverage under Ayushman Bharat
, CDSCO.jpg)